Cambridge, Massachusetts-based biopharmaceutical giant Biogen (Nasdaq: BIIB) has disclosed it will stop manufacturing activity in the Boston area.
The move means its manufacturing facilities in Research Triangle Park will see increased activity. However, the company will not add workers locally. A spokesman says Biogen has the capability with its existing staff of 1,300 workers to meet manufacturing demand.
“We have significantly improved the manufacturing productivity at our facilities over…
Cambridge, Massachusetts-based biopharmaceutical giant Biogen (Nasdaq: BIIB) has disclosed it will stop manufacturing activity in the Boston area.
The move means its manufacturing facilities in Research Triangle Park will see increased activity. However, the company will not add workers locally. A spokesman says Biogen has the capability with its existing staff of 1,300 workers to meet manufacturing demand.
“We have significantly improved the manufacturing productivity at our facilities over…